Functional and Molecular Imaging
The research group was founded in 2013 to integrate expertise in functional, structural and molecular imaging and treatment.
Expanded knowledge of the pathogenesis behind diseases has led to the development of novel therapies.
Functional and molecular imaging modalities are promising for non-invasive diagnosis and evaluation of treatment response at an earlier time point than morphological imaging.
The goals are to individualize diagnostic work-up and treatment, in order to optimize treatment outcome and minimize toxicity.
The group focuses on
- Clinical- and translational studies
- How to optimize image quality and to improve accuracy of disease detection
- In vivo tissue characterization and depiction of disease process
- Treatment response assessment
- Multimodality imaging
- Radionuclide therapies
- Theranostic medicine (simultaneous integration of diagnosis and therapy approaches by the use of the same tracer)
- Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
- Characterization of vascular inflammation including vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
- Detection of inflammation treatment selection and treatment response evaluation using PET and MRI
- Amyloid imaging by 18F-Flutemetamol PET/CT – clinical value and quantitative reference levels
- Radio-immunotherapy for treatment of relapsed CD37+ non-Hodgkin lymphoma (the Betalutin study) and Selective Internal Radiation Therapy (SIRT) with SIR-Spheres
- Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma